NASDAQ · Biotechnology

Immunic, Inc. (IMUX) Stock

$13.81 +3.14% NASDAQ: IMUX Healthcare

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions.

Valuation

MetricValue
Price$13.81
Market Cap$188.11M
P/E Ratio-2.24
P/B Ratio2.67
P/S Ratio0.00
EPS (TTM)$-6.24
52-Week High$15.84
52-Week Low$5.06
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-220.75%
ROA-54.96%
ROCE-72.43%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.14
Current Ratio0.74

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-92.0M$-119.0M$-99.0M$-98.0M$-103.0M
Net Profit$-93.0M$-120.0M$-94.0M$-101.0M$-97.0M
EPS$-39.20$-37.80$-21.10$-10.00$-6.24
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$139.0M$128.0M$54.0M$41.0M$24.0M
Total Liabilities$12.0M$14.0M$25.0M$22.0M$31.0M
Cash$87.0M$107.0M$47.0M$36.0M$15.0M
Borrowings$1.0M$2.0M$1.0M$1.0M$1.0M

Latest News

Immunic to Participate in Investor Conferences in July PR Newswire · Jul 9, 2026 Immunic to Participate in Investor, Industry and Scientific Conferences in June PR Newswire · Jun 10, 2026 Immunic presents new vidofludimus calcium data at multiple sclerosis conference Proactive · May 28, 2026 Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis PR Newswire · May 28, 2026 Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials Proactive · May 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-83.0M$-65.0M$-71.0M$-85.0M$-86.0M
Investing Cash Flow$0$-10.0M$9.0M$-1.0M$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-41.0M$20.0M$-60.0M$-11.0M$-20.0M
Free Cash Flow$-83.0M$-65.0M$-71.0M$-85.0M$-86.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.57
EV / EBITDA-0.02
FCF Yield-45.72%
Quick Ratio0.74
Interest Coverage0.00
Return 1Y74.88%
Return 3Y-41.94%
Return 5Y-84.27%

Ownership

Insiders Held0.97%
Institutions Held46.90%
Institutions Float Held47.37%
Institutional HolderSharesReport Date
Marshall Wace LLP952,9662026-03-31
Aberdeen Group plc824,3942026-03-31
BVF Inc.765,2972026-03-31
Avidity Partners Management, LP669,9412026-03-31
Vanguard Capital Management LLC513,8322026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACET $8.30 +1.22% -0.46 $77.59M 0.00%
ACRV $1.73 +2.37% -0.95 $74.05M 0.00%
BMEA $1.22 +0.00% -1.20 $88.21M 0.00%
CBUS $1.93 +0.00% -0.50 $87.79M 0.00%
LITS $0.91 -2.31% -0.35 $30.88M 0.00%

About Immunic, Inc.

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.

Immunic, Inc. is led by CEO Daniel Vitt, employs 91 people, headquartered in US, publicly traded since 2014.

Immunic, Inc. (IMUX) stock trades at $13.81 with a market capitalization of $188.11M. The stock is valued at a price-to-earnings (P/E) ratio of -2.24, price-to-book of 2.67, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.06 and $15.84, and currently trades 12.8% below its 52-week high.

On profitability, Immunic, Inc. generates a return on equity (ROE) of -220.75%, return on capital employed of -72.43%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: imux.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides